NCT07678073 Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation
| NCT ID | NCT07678073 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Gaziantep |
| Condition | Kidney Disease, End-Stage |
| Study Type | INTERVENTIONAL |
| Enrollment | 68 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 68 participants in total. It began in 2026-03-01 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Renal transplantation is the most effective renal replacement therapy for patients with end-stage renal disease. Ischemia-reperfusion injury may adversely affect graft function and long-term outcomes. Ferroptosis has recently emerged as a potential mechanism involved in ischemia-reperfusion injury, while the mitochondrial-derived peptides humanin and MOTS-c are thought to exert protective effects against oxidative stress. However, the effects of different anesthetic techniques on these biomarkers in kidney transplant recipients have not been investigated. This prospective controlled study aims to compare the effects of sevoflurane general anesthesia (SGA) and combined spinal-epidural anesthesia (CSEA) on serum ferroptosis markers, humanin, and MOTS-c levels in adult kidney transplant recipients. Blood samples will be obtained perioperatively for biomarker analysis. The primary objective of the study is to evaluate the effects of the anesthetic technique on serum ferroptosis markers, humanin, and MOTS-c levels. Secondary objectives include evaluating early graft function and postoperative outcomes by assessing the incidence of delayed graft function, postoperative serum creatinine levels, requirement for dialysis, urine output, length of hospital stay, and the association of these outcomes with perioperative biomarker levels.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18-70 years with American Society of Anesthesiologists (ASA) physical status I-III. * Patients scheduled for elective living-donor allogeneic kidney transplantation. * Patients receiving sevoflurane-based general anesthesia as the anesthetic technique. * Patients receiving combined spinal-epidural anesthesia as the anesthetic technique. Exclusion Criteria: * Patients younger than 18 years or older than 70 years. * Patients undergoing deceased-donor kidney transplantation. * Patients receiving total intravenous anesthesia (TIVA). * Patients who decline to participate in the study or are unable to provide informed consent. * Patients with American Society of Anesthesiologists (ASA) physical status IV or V. * Patients with a history of previous organ transplantation. * Patients with known or suspected mitochondrial disorders. * Patients with a history of chronic corticosteroid use. * Patients requiring red blood cell transfusion intraoperatively or within the first 24 postoperative hours. * Patients with a primary warm ischemia time \>5 minutes, secondary warm ischemia time \>30 minutes, or cold ischemia time \>60 minutes.
Contact & Investigator
Berna KAYA UĞUR, Doç. Dr.
PRINCIPAL INVESTIGATOR
University of Gaziantep
Frequently Asked Questions
Who can join the NCT07678073 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Kidney Disease, End-Stage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07678073 currently recruiting?
Yes, NCT07678073 is actively recruiting participants. Contact the research team at drkadirucar@gmail.com for enrollment information.
Where is the NCT07678073 trial being conducted?
This trial is being conducted at Gaziantep, Turkey (Türkiye).
Who is sponsoring the NCT07678073 clinical trial?
NCT07678073 is sponsored by University of Gaziantep. The principal investigator is Berna KAYA UĞUR, Doç. Dr. at University of Gaziantep. The trial plans to enroll 68 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.